|
|
| G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity
|
ISO
|
clothiapine results in decreased activity of KCNH2 protein
|
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
|
|
| G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
decreases activity
|
ISO
|
Quetiapine Fumarate results in decreased activity of ABCB1 protein
|
CTD |
PMID:16810505 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
| G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
Quetiapine Fumarate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]
|
CTD |
PMID:18834354 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
| G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
EXP
|
Quetiapine Fumarate inhibits the reaction [APP protein modified form affects the activity of CAT protein]; Quetiapine Fumarate inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species]
|
CTD |
PMID:15948179 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
EXP
|
Quetiapine Fumarate results in increased expression of BAX protein
|
CTD |
PMID:16462815 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bdnf
|
brain-derived neurotrophic factor
|
increases expression
|
EXP
|
Quetiapine Fumarate results in increased expression of BDNF protein
|
CTD |
PMID:17442489 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
| G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
Quetiapine Fumarate inhibits the reaction [APP protein modified form affects the activity of CAT protein]
|
CTD |
PMID:15948179 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Cnr1
|
cannabinoid receptor 1
|
decreases expression
|
ISO
|
Quetiapine Fumarate results in decreased expression of CNR1 protein
|
CTD |
PMID:31220554 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252
|
|
| G
|
Cnr2
|
cannabinoid receptor 2
|
increases expression
|
ISO
|
Quetiapine Fumarate results in increased expression of CNR2 protein
|
CTD |
PMID:31220554 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961
|
|
| G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
Carbamazepine promotes the reaction [CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate]; CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate]
|
CTD |
PMID:16390352 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
| G
|
Drd2
|
dopamine receptor D2
|
multiple interactions
|
EXP
|
Quetiapine Fumarate promotes the reaction [Dopamine binds to DRD2 protein]
|
CTD |
PMID:15716360 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339
|
|
| G
|
Htr2a
|
5-hydroxytryptamine receptor 2A
|
multiple interactions
|
ISO
|
Quetiapine Fumarate inhibits the reaction [Ketanserin binds to HTR2A protein]
|
CTD |
PMID:16314884 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619
|
|
| G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
multiple interactions decreases activity
|
ISO
|
Quetiapine Fumarate inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Quetiapine Fumarate results in decreased activity of KCNH2 protein
|
CTD |
PMID:21158687 PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
| G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
decreases metabolic processing
|
ISO
|
Quetiapine Fumarate results in decreased metabolism of MAP1LC3B protein
|
CTD |
PMID:31220554 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
| G
|
Mbp
|
myelin basic protein
|
multiple interactions
|
ISO
|
Quetiapine Fumarate inhibits the reaction [Cuprizone results in decreased activity of MBP protein]
|
CTD |
PMID:18938062 |
|
NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174
|
|
| G
|
Mlkl
|
mixed lineage kinase domain like pseudokinase
|
multiple interactions
|
ISO
|
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]; AM 1241 inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; AM 1241 inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]; AM 281 inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; AM 281 inhibits the reaction [Quetiapine Fumarate results in increased phosphorylation of MLKL protein]; Quetiapine Fumarate results in increased expression of and affects the localization of MLKL protein; Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein; Rimonabant inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]
|
CTD |
PMID:31220554 |
|
NCBI chr19:56,186,860...56,213,886
Ensembl chr19:56,186,860...56,213,858
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions decreases activity affects oxidation
|
ISO
|
Quetiapine Fumarate inhibits the reaction [[MPO protein results in increased metabolism of chlorodimedone] which results in increased abundance of Hypochlorous Acid]; Quetiapine Fumarate inhibits the reaction [MPO protein results in increased abundance of Hypochlorous Acid] Quetiapine Fumarate results in decreased activity of MPO protein MPO protein affects the oxidation of Quetiapine Fumarate
|
CTD |
PMID:35575633 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Ndufv2
|
NADH:ubiquinone oxidoreductase core subunit V2
|
increases expression
|
EXP
|
Quetiapine Fumarate results in increased expression of NDUFV2 mRNA
|
CTD |
PMID:19441803 |
|
NCBI chr 9:113,137,305...113,157,571
Ensembl chr 9:113,137,306...113,157,520
|
|
| G
|
Ngfr
|
nerve growth factor receptor
|
decreases expression
|
EXP
|
Quetiapine Fumarate results in decreased expression of NGFR mRNA
|
CTD |
PMID:12111809 PMID:16513140 |
|
NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305
|
|
| G
|
Prl
|
prolactin
|
decreases expression increases secretion
|
ISO
|
Quetiapine Fumarate results in decreased expression of PRL protein Quetiapine Fumarate results in increased secretion of PRL protein
|
CTD |
PMID:16379509 PMID:18063941 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
| G
|
Ripk1
|
receptor interacting serine/threonine kinase 1
|
multiple interactions increases expression
|
ISO
|
AM 281 inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK1 protein]; Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK1 protein]
|
CTD |
PMID:31220554 |
|
NCBI chr17:31,044,983...31,077,167
Ensembl chr17:31,044,994...31,077,167
|
|
| G
|
Ripk3
|
receptor-interacting serine-threonine kinase 3
|
multiple interactions increases expression
|
ISO
|
Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK3 protein]
|
CTD |
PMID:31220554 |
|
NCBI chr15:33,253,071...33,262,025
Ensembl chr15:33,253,071...33,262,025
|
|
| G
|
Slc22a5
|
solute carrier family 22 member 5
|
multiple interactions
|
ISO
|
Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
|
CTD |
PMID:30465787 |
|
NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077
|
|
| G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions increases expression
|
ISO EXP
|
Quetiapine Fumarate inhibits the reaction [Cuprizone results in decreased activity of SOD1 protein] Quetiapine Fumarate results in increased expression of SOD1 mRNA Quetiapine Fumarate inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]
|
CTD |
PMID:12111809 PMID:12752374 PMID:18938062 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
|
|
| G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
increases expression
|
EXP
|
tianeptine results in increased expression of ABCC2 mRNA
|
CTD |
PMID:27765674 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
| G
|
Abcg5
|
ATP binding cassette subfamily G member 5
|
increases expression
|
EXP
|
tianeptine results in increased expression of ABCG5 mRNA
|
CTD |
PMID:27765674 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376
|
|
| G
|
Abcg8
|
ATP binding cassette subfamily G member 8
|
increases expression
|
EXP
|
tianeptine results in increased expression of ABCG8 mRNA
|
CTD |
PMID:27765674 |
|
NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:15,698,448...15,717,730
|
|
| G
|
Angptl3
|
angiopoietin-like 3
|
decreases expression
|
ISO
|
tianeptine results in decreased expression of ANGPTL3 mRNA
|
CTD |
PMID:27089845 |
|
NCBI chr 5:118,818,494...118,825,531
Ensembl chr 5:118,818,499...118,826,444
|
|
| G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
tianeptine inhibits the reaction [Indomethacin results in increased activity of CAT protein]
|
CTD |
PMID:19497431 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Cnr2
|
cannabinoid receptor 2
|
increases expression
|
EXP
|
tianeptine results in increased expression of CNR2 protein
|
CTD |
PMID:28866072 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961
|
|
| G
|
Drd2
|
dopamine receptor D2
|
decreases expression
|
EXP
|
tianeptine results in decreased expression of DRD2 mRNA
|
CTD |
PMID:11981225 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339
|
|
| G
|
Igfbp1
|
insulin-like growth factor binding protein 1
|
increases expression
|
ISO
|
tianeptine results in increased expression of IGFBP1 mRNA
|
CTD |
PMID:27089845 |
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
tianeptine inhibits the reaction [Indomethacin results in increased activity of MPO protein]
|
CTD |
PMID:19497431 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Oprm1
|
opioid receptor, mu 1
|
increases activity
|
ISO
|
tianeptine results in increased activity of OPRM1 protein
|
CTD |
PMID:32734307 |
|
NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756
|
|
| G
|
Slc10a1
|
solute carrier family 10 member 1
|
decreases expression
|
EXP
|
tianeptine results in decreased expression of SLC10A1 mRNA
|
CTD |
PMID:27765674 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944
|
|
| G
|
Slc6a4
|
solute carrier family 6 member 4
|
multiple interactions
|
ISO
|
tianeptine binds to and results in decreased activity of SLC6A4 protein
|
CTD |
PMID:16272152 |
|
NCBI chr10:62,322,688...62,357,060
Ensembl chr10:62,324,254...62,357,056
|
|
| G
|
Slco1a1
|
solute carrier organic anion transporter family, member 1a1
|
decreases expression
|
EXP
|
tianeptine results in decreased expression of SLCO1A1 mRNA
|
CTD |
PMID:27765674 |
|
NCBI chr 4:176,606,924...176,682,027
Ensembl chr 4:176,607,687...176,681,992
|
|
| G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
increases expression
|
ISO
|
tianeptine results in increased expression of SREBF1 mRNA
|
CTD |
PMID:27089845 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|